Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial)

Dec 1, 2016 by in CARDIOLOGY Comments Off on Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial)

Despite the well-established benefits of mineralocorticoid receptor agonists (MRAs) in heart failure with reduced ejection fraction, safety concerns remain in patients with concomitant diabetes mellitus (DM) because of common renal…

read more

Long-Term Outcome of Defibrillator Recipients Included in the Federal Audit Conducted by the Department of Justice

Dec 1, 2016 by in CARDIOLOGY Comments Off on Long-Term Outcome of Defibrillator Recipients Included in the Federal Audit Conducted by the Department of Justice

Institutions across the United States have been subjected to a federal audit for defibrillator implantable cardioverter defibrillator [ICD] implantations that violated the Centers for Medicare and Medicaid payment policy. We…

read more

Comparison of Safety of Sotalol Versus Amiodarone in Patients With Atrial Fibrillation and Coronary Artery Disease

Dec 1, 2016 by in CARDIOLOGY Comments Off on Comparison of Safety of Sotalol Versus Amiodarone in Patients With Atrial Fibrillation and Coronary Artery Disease

Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF). Although randomized studies have found that sotalol can significantly delay time…

read more

Predicting Long-Term Cardiovascular Risk Using the Mayo Clinic Cardiovascular Risk Score in a Referral Population

Dec 1, 2016 by in CARDIOLOGY Comments Off on Predicting Long-Term Cardiovascular Risk Using the Mayo Clinic Cardiovascular Risk Score in a Referral Population

Exercise testing provides valuable information but is rarely integrated to derive a risk prediction model in a referral population. In this study, we assessed the predictive value of conventional cardiovascular…

read more

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

Dec 1, 2016 by in CARDIOLOGY Comments Off on Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease, with limited treatment options. This analysis evaluated the effect of a monoclonal antibody to proprotein convertase subtilisin/kexin 9, alirocumab 150 mg…

read more

Temporal Trends in the Occurrence and Outcomes of Atrial Fibrillation in Patients With Acute Myocardial Infarction (from the Atherosclerosis Risk in Communities Surveillance Study)

Dec 1, 2016 by in CARDIOLOGY Comments Off on Temporal Trends in the Occurrence and Outcomes of Atrial Fibrillation in Patients With Acute Myocardial Infarction (from the Atherosclerosis Risk in Communities Surveillance Study)

Atrial fibrillation (AF) frequently coexists in the setting of myocardial infarction (MI), being associated with increased mortality. Nonetheless, temporal trends in the occurrence of AF complicating MI and in the…

read more

Comparison of Epicardial Adipose Tissue Volume and Coronary Artery Disease Severity in Asymptomatic Adults With Versus Without Diabetes Mellitus

Dec 1, 2016 by in CARDIOLOGY Comments Off on Comparison of Epicardial Adipose Tissue Volume and Coronary Artery Disease Severity in Asymptomatic Adults With Versus Without Diabetes Mellitus

Epicardial adipose tissue (EAT) has been shown to have important effects on the development of coronary artery disease (CAD) through local paracrine influences on the vascular bed. We compared a…

read more
Get Clinical Tree app for offline access